Skip to Main Content
Advertisement
Close
AACR Journals
Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics
For Authors
Information for Authors
Author Services
Journal Awards
About Us
AACR Journals
Advertising
Permissions & Reprints
Subscriptions
Submit
Article Collections
Cancer Hallmarks Collection
Hot Topics
Editors' Picks
COVID-19
Alerts
News
Cancer Hallmarks
Webinars
Search Dropdown Menu
header search
search input
Search input auto suggest
Search
Advanced Search
User Tools Dropdown
Register
Sign In
Toggle Menu
Menu
About
The Journal
Editorial Board
AACR Journals
Subscriptions
Permissions and Reprints
Articles
Online First
Issues
Meeting Abstracts
Collection: Editors' Picks
COVID-19
First Disclosures
For Authors
Information for Authors
Author Services
Outstanding Journal Article Award
Submit
Alerts
News
Cancer Hallmarks
Webinars
Skip Nav Destination
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of
6-Diazo-5-oxo-L-norleucine
Mol Cancer Ther
(2018) 17 (9): 1824–1832.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to
our privacy policy.
Accept
RSS Feeds